Late-onset Parkinsonism in NFκB/c-Rel-deficient mice

被引:71
作者
Baiguera, Cristina [1 ,2 ]
Alghisi, Manuela [1 ,2 ]
Pinna, Annalisa [3 ,4 ,5 ]
Bellucci, Arianna [1 ,2 ]
De Luca, Maria Antonietta [4 ,5 ]
Frau, Lucia [3 ,4 ,5 ]
Morelli, Micaela [3 ,4 ,5 ]
Ingrassia, Rosaria [1 ,2 ]
Benarese, Marina [1 ,2 ]
Porrini, Vanessa [1 ,2 ]
Pellitteri, Michele [6 ]
Bertini, Giuseppe [6 ]
Fabene, Paolo Francesco [6 ]
Sigala, Sandra [1 ,2 ]
Spillantini, Maria Grazia [7 ]
Liou, Hsiou-Chi [8 ]
Spano, Pier Franco [1 ,2 ,9 ]
Pizzi, Marina [1 ,2 ,9 ]
机构
[1] Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy
[2] Natl Inst Neurosci, I-25123 Brescia, Italy
[3] Inst Neurosci, Natl Res Council, I-09124 Cagliari, Italy
[4] Univ Cagliari, Dept Biomed Sci, I-09124 Cagliari, Italy
[5] Univ Cagliari, Natl Inst Neurosci, I-09124 Cagliari, Italy
[6] Univ Verona, Dept Neurol Neuropsychol Morphol & Motor Sci, I-37134 Verona, Italy
[7] Univ Cambridge, Dept Clin Neurosci, Brain Repair Ctr, Cambridge CB2 0PY, England
[8] Cornell Univ, Weill Med Coll, Dept Immunol, New York, NY 10065 USA
[9] IRCCS San Camillo Hosp, Venice, Italy
关键词
Parkinson's disease; NF kappa B/c-Rel; alpha-synuclein; motor impairments; L-DOPA; HIGH-FREQUENCY STIMULATION; MGLU5 RECEPTOR AGONISTS; FACTOR C-REL; DOPAMINERGIC-NEURONS; TRANSCRIPTION FACTOR; ALPHA-SYNUCLEIN; SUBTHALAMIC NUCLEUS; CEREBRAL-ISCHEMIA; ALZHEIMER-DISEASE; SUBSTANTIA-NIGRA;
D O I
10.1093/brain/aws193
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Activation of the nuclear factor kappa B/c-Rel can increase neuronal resilience to pathological noxae by regulating the expression of pro-survival manganese superoxide dismutase (MnSOD, now known as SOD2) and Bcl-xL genes. We show here that c-Rel-deficient (c-rel(-/-)) mice developed a Parkinson's disease-like neuropathology with ageing. At 18 months of age, c-rel(-/-) mice exhibited a significant loss of dopaminergic neurons in the substantia nigra pars compacta, as assessed by tyrosine hydroxylase-immunoreactivity and Nissl staining. Nigral degeneration was accompanied by a significant loss of dopaminergic terminals and a significant reduction of dopamine and homovanillic acid levels in the striatum. Mice deficient of the c-Rel factor exhibited a marked immunoreactivity for fibrillary a-synuclein in the substantia nigra pars compacta as well as increased expression of divalent metal transporter 1 (DMT1) and iron staining in both the substantia nigra pars compacta and striatum. Aged c-rel(-/-) mouse brain were characterized by increased microglial reactivity in the basal ganglia, but no astrocytic reaction. In addition, c-rel(-/-) mice showed age-dependent deficits in locomotor and total activity and various gait-related deficits during a catwalk analysis that were reminiscent of bradykinesia and muscle rigidity. Both locomotor and gait-related deficits recovered in c-rel(-/-) mice treated with L-3,4-dihydroxyphenylalanine. These data suggest that c-Rel may act as a regulator of the substantia nigra pars compacta resilience to ageing and that aged c-rel(-/-) mice may be a suitable model of Parkinson's disease.
引用
收藏
页码:2750 / 2765
页数:16
相关论文
共 65 条
[1]
c-Rel, an NF-κB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation [J].
Ahn, Hyung Jin ;
Hernandez, Caterina M. ;
Levenson, Jonathan M. ;
Lubin, Farah D. ;
Liou, Hsiou-Chi ;
Sweatt, J. David .
LEARNING & MEMORY, 2008, 15 (07) :539-549
[2]
Space, time and dopamine [J].
Arbuthnott, Gordon W. ;
Wickens, Jeff .
TRENDS IN NEUROSCIENCES, 2007, 30 (02) :62-69
[3]
The Genetics of Parkinson Disease [J].
Bekris, Lynn M. ;
Mata, Ignacio F. ;
Zabetian, Cyrus P. .
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2010, 23 (04) :228-242
[4]
Bellucci A, 2012, BRAIN RES IN PRESS
[5]
Bernard D, 2001, CANCER RES, V61, P2656
[6]
Bethea JR, 1998, J NEUROSCI, V18, P3251
[7]
Staging of brain pathology related to sporadic Parkinson's disease [J].
Braak, H ;
Del Tredici, K ;
Rüb, U ;
de Vos, RAI ;
Steur, ENHJ ;
Braak, E .
NEUROBIOLOGY OF AGING, 2003, 24 (02) :197-211
[8]
NF-κB as a therapeutic target in neurodegenerative diseases [J].
Camandola, Simonetta ;
Mattson, Mark P. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (02) :123-132
[9]
Cardozo-Pelaez F, 1999, MOVEMENT DISORD, V14, P972, DOI 10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO
[10]
2-0